Integrated Diagnostics Holdings (LSE:IDHC) FCF Yield %: 9.98 (As of Jun. 28, 2026) — 134% Above Median


LSE:IDHC Integrated Diagnostics Holdings PLC LSE:IDHC
58 GF Score
Price $0.50
GF Value $0.57
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Integrated Diagnostics Holdings FCF Yield %?

Integrated Diagnostics Holdings LSE:IDHC 58 FCF Yield % is 9.98 as of Jun. 28, 2026, which is 134% above its 10-year median of 4.27. GuruFocus rates LSE:IDHC with a GF Score™ of 58/100 and a GF Value™ of $0.57 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Integrated Diagnostics Holdings ranks better than 93.93% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Integrated Diagnostics Holdings's Trailing 12-Month Free Cash Flow is $29.12 Mil, and Market Cap is $291.83 Mil. Therefore, Integrated Diagnostics Holdings's FCF Yield % for today is 9.98%.

The historical rank and industry rank for Integrated Diagnostics Holdings's FCF Yield % or its related term are showing as below:

LSE:IDHC' s FCF Yield % Range Over the Past 10 Years
Min: -8.99   Med: 4.27   Max: 25.11
Current: 9.98


During the past 13 years, the highest FCF Yield % of Integrated Diagnostics Holdings was 25.11%. The lowest was -8.99%. And the median was 4.27%.

LSE:IDHC's FCF Yield % is ranked better than
93.93% of 214 companies
in the Medical Diagnostics & Research industry
Industry Median: -1.455 vs LSE:IDHC: 9.98

Integrated Diagnostics Holdings's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.


Integrated Diagnostics Holdings FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Integrated Diagnostics Holdings FCF Yield % Related Terms


Integrated Diagnostics Holdings FCF Yield % Historical Data

* Premium members only.

The historical data trend for Integrated Diagnostics Holdings's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Integrated Diagnostics Holdings FCF Yield % Chart

Integrated Diagnostics Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.56 -1.07 3.31 10.46 6.72

Integrated Diagnostics Holdings Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.78 0.00 0.00 0.00 0.00

LSE:IDHC vs TMO, DHR, IDXX: FCF Yield % Comparison

For the Diagnostics & Research subindustry, Integrated Diagnostics Holdings's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integrated Diagnostics Holdings FCF Yield % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Integrated Diagnostics Holdings's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Integrated Diagnostics Holdings's FCF Yield % falls into.


LSE:IDHC
58GF Score
Integrated Diagnostics Holdings PLC LSE:IDHC
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Integrated Diagnostics Holdings FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Integrated Diagnostics Holdings's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=29.115 / 433.08787
=6.72%

Integrated Diagnostics Holdings's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=0 * 4 / 325.54256
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of 9.98 mean?
Integrated Diagnostics Holdings (LSE:IDHC) has a FCF Yield % of 9.98 as of Jun. 28, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Integrated Diagnostics Holdings and its competitors. This is 134% above median its historical median of 4.27. According to the industry distribution chart, Integrated Diagnostics Holdings ranks #13 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 6.1%.
Is Integrated Diagnostics Holdings' FCF Yield % too high?
Integrated Diagnostics Holdings' current FCF Yield % of 9.98 is 134% above median its 10-year median of 4.27. Based on the distribution chart, Integrated Diagnostics Holdings ranks #13 out of 214 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Integrated Diagnostics Holdings has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integrated Diagnostics Holdings' FCF Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integrated Diagnostics Holdings ranks #13 out of 214 companies for FCF Yield %. This places Integrated Diagnostics Holdings in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Integrated Diagnostics Holdings and its competitors. Integrated Diagnostics Holdings's current FCF Yield % is 9.98, which is 134% above median its own 10-year median of 4.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integrated Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integrated Diagnostics Holdings (LSE:IDHC) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.57, compared to a current price of $0.50 — trading 11.9% below its estimated fair value. The current FCF Yield % is 9.98, which is 134% above median its 10-year median of 4.27. Integrated Diagnostics Holdings' overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Integrated Diagnostics Holdings (LSE:IDHC), the current FCF Yield % is 9.98 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Integrated Diagnostics Holdings (LSE:IDHC) Overvalued in 2026?

Based on GuruFocus' analysis, Integrated Diagnostics Holdings stock appears to be undervalued. The current stock price of $0.50 is trading 11.9% below its estimated GF Value™ of $0.57. GuruFocus considers Integrated Diagnostics Holdings to be Modestly Undervalued.

Key valuation signals for LSE:IDHC:

  • FCF Yield %: 9.98 (134% above median its 10-year median of 4.27)
  • GF Value™: $0.57 vs. price of $0.50 (11.9% below fair value)
  • GF Score™: 58/100 with 7 warning signs

No single metric tells the full story. See the LSE:IDHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Integrated Diagnostics Holdings Business Description

Address 12 Castle Street, St Helier, JEY, JE2 3RT
Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider, operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan, Echo-Lab in Nigeria, and Biolab KSA in Saudi Arabia. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segments: the Contract Segment, which generates key revenue, and the Walk-in Segment. It derives a majority of its revenue from services offered in Egypt.
58GF Score

Get the complete analysis for LSE:IDHC

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.50
Price
$0.57
GF Value